Skip to main content
Top
Published in: Journal of Gastrointestinal Cancer 2/2020

01-06-2020 | Gallbladder Cancer | Original Research

Ruthenium Complex Induce Cell Death in G-415 Gallbladder Cancer Cells

Authors: Hernán Villota, Sebastian Pizarro, Francisco Gajardo, Álvaro Delgadillo, Fabián Cortés-Mancera, Giuliano Bernal

Published in: Journal of Gastrointestinal Cancer | Issue 2/2020

Login to get access

Abstract

Purpose

In this work, we present a recently developed ruthenium complex that shows anticancer activity in gallbladder cancer cells.

Methods

After the synthesis of the new ruthenium complexes, the antiproliferative, cytotoxicity, and apoptosis activities were evaluated in vitro by the triple assay ApoTox-Glo. Then, the transcription levels of genes related to apoptosis were evaluated by real-time PCR (q-PCR).

Results

The ruthenium complex, called Ru-UCN3, inhibits the proliferation of gallbladder cancer cells G-415 by means of apoptosis, which was demonstrated by the overexpression of the pro-apoptotic genes Puma, Diablo, and Caspasa-9 together with the repression of the anti-apoptotic genes Bcl-xL and Bcl-2. In addition, we found strong caspase 3/7 activity in the cells at 24 h of the Ru-UCN3 exposure, which was evaluated by the triple ApoTox-Glo assay.

Conclusion

The new ruthenium complexes evaluated had an inhibitory effect on G-415 cells. We think that Ru-UCN3 could be a promising anticancer agent, which should be explored with more in vitro and in vivo assays and probably with the chemical modulation of this molecule.
Literature
7.
go back to reference Thongprasert S, Napapan S, Charoentum C, Moonprakan S. Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma. Ann Oncol. 2005;16:279–81. PMID: 15668284.CrossRef Thongprasert S, Napapan S, Charoentum C, Moonprakan S. Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma. Ann Oncol. 2005;16:279–81. PMID: 15668284.CrossRef
9.
go back to reference Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273–81.CrossRef Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273–81.CrossRef
11.
go back to reference Klajner M, Licona C, Fetzer L, Hebraud P, Mellitzer G, Pfeffer M, et al. Subcellular localization and transport kinetics of ruthenium organometallic anticancer compounds in living cells: a dose-dependent role for amino acid and iron transporters. Inorg Chem. 2014;53(10):5150–8. https://doi.org/10.1021/ic500250e Epub 2014 May 1.CrossRefPubMed Klajner M, Licona C, Fetzer L, Hebraud P, Mellitzer G, Pfeffer M, et al. Subcellular localization and transport kinetics of ruthenium organometallic anticancer compounds in living cells: a dose-dependent role for amino acid and iron transporters. Inorg Chem. 2014;53(10):5150–8. https://​doi.​org/​10.​1021/​ic500250e Epub 2014 May 1.CrossRefPubMed
14.
go back to reference Allardyce CS, Dyson PJ. Ruthenium in medicine current clinical uses and future prospects. Platin Met Rev. 2001;45(2):62–69. Allardyce CS, Dyson PJ. Ruthenium in medicine current clinical uses and future prospects. Platin Met Rev. 2001;45(2):62–69.
17.
go back to reference Oun R, Moussa YE, Wheate NJ. The side effects of platinum-based chemotherapy drugs: a review for chemists. Dalton Trans. 2018;47:6645–53.CrossRef Oun R, Moussa YE, Wheate NJ. The side effects of platinum-based chemotherapy drugs: a review for chemists. Dalton Trans. 2018;47:6645–53.CrossRef
19.
go back to reference Ramírez-Rivera S, Pizarro S, Gallardo M, Gajardo F, Delgadillo A, De La Fuente-Ortega E, et al. Anticancer activity of two novel ruthenium compounds in gastric cancer cells. Life Sci. 2018;213:57–65.CrossRef Ramírez-Rivera S, Pizarro S, Gallardo M, Gajardo F, Delgadillo A, De La Fuente-Ortega E, et al. Anticancer activity of two novel ruthenium compounds in gastric cancer cells. Life Sci. 2018;213:57–65.CrossRef
20.
go back to reference Lai S-H, Jiang G-B, Yao J-H, Li W, Han B-J, Cheng Z, et al. Cytotoxic activity, DNA damage, cellular uptake, apoptosis and western blot analysis of ruthenium(II) polypyridyl complex against human lung adecarcinoma A549 cell. J Inorg Biochem. 2015;152:1–9.CrossRef Lai S-H, Jiang G-B, Yao J-H, Li W, Han B-J, Cheng Z, et al. Cytotoxic activity, DNA damage, cellular uptake, apoptosis and western blot analysis of ruthenium(II) polypyridyl complex against human lung adecarcinoma A549 cell. J Inorg Biochem. 2015;152:1–9.CrossRef
24.
go back to reference Villota H, Pizarro S, Gajardo F, Delgadillo Á, Cortés-Mancera F, Bernal G. Selective cytotoxicity of a novel compound based on ruthenium II in a gallbladder carcinoma cell line. In: Torres I, Bustamante J, Sierra D, editors. VII Latin American Congress on Biomedical Engineering CLAIB 2016, Bucaramanga, Santander, Colombia, October 26th -28th, 2016. IFMBE proceedings, vol. 60. Singapore: Springer; 2017. https://doi.org/10.1007/978-981-10-4086-3_74.CrossRef Villota H, Pizarro S, Gajardo F, Delgadillo Á, Cortés-Mancera F, Bernal G. Selective cytotoxicity of a novel compound based on ruthenium II in a gallbladder carcinoma cell line. In: Torres I, Bustamante J, Sierra D, editors. VII Latin American Congress on Biomedical Engineering CLAIB 2016, Bucaramanga, Santander, Colombia, October 26th -28th, 2016. IFMBE proceedings, vol. 60. Singapore: Springer; 2017. https://​doi.​org/​10.​1007/​978-981-10-4086-3_​74.CrossRef
25.
go back to reference Villota H, Pizarro S, Gajardo F, Delgadillo Á, Cortés-Mancera F, Bernal G. Apoptosis induced by a novel ruthenium II complex in a gallbladder carcinoma cell line. In: Torres I, Bustamante J, Sierra D, editors. VII Latin American congress on Biomedical Engineering CLAIB 2016, Bucaramanga, Santander, Colombia, October 26th -28th, 2016. IFMBE proceedings, vol. 60. Singapore: Springer; 2017. https://doi.org/10.1007/978-981-10-4086-3_75.CrossRef Villota H, Pizarro S, Gajardo F, Delgadillo Á, Cortés-Mancera F, Bernal G. Apoptosis induced by a novel ruthenium II complex in a gallbladder carcinoma cell line. In: Torres I, Bustamante J, Sierra D, editors. VII Latin American congress on Biomedical Engineering CLAIB 2016, Bucaramanga, Santander, Colombia, October 26th -28th, 2016. IFMBE proceedings, vol. 60. Singapore: Springer; 2017. https://​doi.​org/​10.​1007/​978-981-10-4086-3_​75.CrossRef
28.
29.
go back to reference Hoek J, Bloemendal KM, van der Velden LAA, van Diessen JNA, van Werkhoven E, Klop WMC, et al. Nefrotoxicidad como un factor limitante de la dosis en un régimen de quimiorradioterapia basada en cisplatino a dosis altas para los carcinomas de cabeza y cuello. Cánceres. 2016;8(2):21. https://doi.org/10.3390/cancers8020021.CrossRef Hoek J, Bloemendal KM, van der Velden LAA, van Diessen JNA, van Werkhoven E, Klop WMC, et al. Nefrotoxicidad como un factor limitante de la dosis en un régimen de quimiorradioterapia basada en cisplatino a dosis altas para los carcinomas de cabeza y cuello. Cánceres. 2016;8(2):21. https://​doi.​org/​10.​3390/​cancers8020021.CrossRef
Metadata
Title
Ruthenium Complex Induce Cell Death in G-415 Gallbladder Cancer Cells
Authors
Hernán Villota
Sebastian Pizarro
Francisco Gajardo
Álvaro Delgadillo
Fabián Cortés-Mancera
Giuliano Bernal
Publication date
01-06-2020
Publisher
Springer US
Published in
Journal of Gastrointestinal Cancer / Issue 2/2020
Print ISSN: 1941-6628
Electronic ISSN: 1941-6636
DOI
https://doi.org/10.1007/s12029-019-00278-x

Other articles of this Issue 2/2020

Journal of Gastrointestinal Cancer 2/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.